Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
about
HIV-1 neutralizing antibodies: understanding nature's pathwaysA novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsCharacterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolateImproved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccinesCrosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodiesImproved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationCharacterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structureThe ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable regionMolecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
P2860
Q27000480-E8C7C634-95D1-4C54-A471-44F2E038A1B5Q31143293-32FC6DE6-CDF3-4DA4-887C-AA90885CCF3FQ33737723-0B33C235-7BD2-4E4B-B731-CFACE79C7005Q33806056-D9612078-74F7-43A3-9EFF-436B11C1869BQ33811940-ED118C6E-00D7-4841-87F8-88720120D9FFQ33836042-790D95C2-A529-4729-BF78-3205239CFAD5Q33839981-D19B5CE5-B226-4CBD-978F-6A5D7D2D4E54Q33842152-48F99342-ECE8-477D-BCB7-4A8CC8C61A45Q33842286-15EAA5D9-38D2-4AA1-A3F6-823C0FA6DEE0Q33854615-A16026EC-9654-4C6B-8892-54F7E5E174A6Q33916676-8967EBDC-6012-4FF0-B4C8-C0D45D5216CDQ34154514-9D17441C-7E81-45B9-9DA2-4B800DFC9F54Q34332284-DC68FBDA-1396-4040-AFCC-875549C4F13FQ34999293-E42C2254-157F-425D-8BCE-51FE8AE20D9AQ35077716-27E6E3C2-15CA-4C77-A40B-A03BD46E4F5DQ35122067-87EEEF1D-7AC4-4835-8C42-6994111257CFQ35569049-A1B7A118-8847-4D9E-AE6D-2C2C137D0B3AQ35666057-A12C94F6-1B84-4C5C-A900-47DF96B0F6C7Q35883032-FD152838-7B8E-4575-8003-B925D5B961EAQ36525047-45A60831-E801-4BFA-B5EC-AADF1067D529Q36804634-484DA99E-F607-4CF8-82D2-71839E27E364Q37596552-ADF4A2AA-8F5B-4784-A79C-650D780840CAQ37742938-24E538C8-2A9B-4FC4-86E4-50319A251EE9Q39588870-4C3AE035-CB01-441D-92E0-4C4DF23C9412Q39602963-26236F86-7A6E-475A-9995-F5EE5344CF1DQ39748810-D90E9018-A583-4E47-A0FD-F0461715EA0B
P2860
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@ast
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@en
type
label
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@ast
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@en
prefLabel
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@ast
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@en
P2093
P2860
P1433
P1476
Cross-subtype neutralizing ant ...... iciency virus type 1 envelope.
@en
P2093
Loomis-Price LD
Mascola JR
Sinangil F
VanCott TC
Zitomersky N
P2860
P304
P577
1999-06-01T00:00:00Z